Long
Long
Long
Long
Long
Long
Long 
Breaking: UnitedHealth Group Incorporated (UNH) Up 4% PremarketThe share price of UnitedHealth Group Incorporated (NYSE: NYSE:UNH ) is up 4% in Tuesday's premarket session as the company reports earnings results 28 October, 2025 before the bell.
UnitedHealth Group raised its 2025 earnings outlook to reflect net earnings of at least $14.90 per share and adjusted net earnings of at least $16.25 per share.
Third Quarter 2025 Key Performance Metrics
Consolidated revenues of $113.2 billion, up 12% year-over-year.
Earnings from operations were $4.3 billion; net margin of 2.1%.
Adjusted EPS of $2.92; GAAP EPS of $2.59.
Medical care ratio (MCR) of 89.9% was in line with expectations outlined in the second quarter 2025.
Operating cost ratio of 13.5% reflecting investments to support future growth.
UnitedHealthcare revenues grew 16% year-over-year to $87.1 billion, driven by growth in Medicare & Retirement and Community & State; UnitedHealthcare served 50.1 million consumers domestically, up 795,000 year-over-year.
Optum revenues grew 8% year-over-year to $69.2 billion, driven by growth in Optum Rx.
September 30, 2025, debt-to-capital ratio of 44.1% unchanged from the second quarter 2025 and inclusive of the impact of closing the Amedisys transaction on August 14, 2025.
Technical Outlook
With the RSI at 58, NYSE:UNH is poised to break the $381 resistant zone paving the way for a much more greater strides. Similarly, on a more bullish tone, the stock's moving averages have cross paths indicating possible resurgence of a golden cross. Long 
UNH Stock Technical Outlook – Bullish Momentum Confirmed😎 UNH Wealth Heist: Swing Trade Strategy Map 🤑💰
Asset: UnitedHealth Group Incorporated ( NYSE:UNH )
Market: US Stock
Market Strategy: Swing Trade (Thief Style 🕵️♂️)
📈 The Setup: Bullish Breakout in Sight! 🚀
Ladies and Gentlemen, welcome to the Thief OG playbook! 📖 NYSE:UNH is setting up for a potential bullish run, and we’re ready to layer our entries like masterminds! 🧠 Here’s the breakdown of this sneaky swing trade setup:
🌟 Bullish Trend Confirmation: The chart is screaming uptrend! We’ve got strong upside pressure from a demand zone 📍, signaling buyers are ready to pounce.
✨ Golden Cross Alert: The Hull Moving Average (HMA) at 786 periods has crossed above the price candles, confirming a bullish momentum shift. 🚀
🐍 Re-accumulation Phase: The stock is consolidating, building energy for the next leg up. It’s like NYSE:UNH is coiling for a big breakout! 💥
🕵️♂️ Entry Plan: The Thief Layering Strategy 🎯
We’re not just entering; we’re layering our entries like pros! 😎 The Thief Strategy uses multiple buy limit orders to scale into the trade with precision. Here’s how to set it up:
📊 Entry Levels: Place buy limit orders at $320.00, $330.00, $340.00, $350.00.
Pro Tip: Feel free to add more layers based on your risk appetite and account size! More layers = more chances to catch the move.
🔍 Why Layering?: This method spreads your entry across key support levels, reducing risk and maximizing potential. It’s like planting multiple traps for profits! 🪤
🛑 Stop Loss: Protect Your Loot! 🔒
🛡️ Thief Stop Loss: Set a stop loss at $300.00.
📝 Note: Dear Thief OGs, this is my suggested stop loss, but it’s your heist! Adjust based on your risk tolerance. Take the money and run at your own discretion! 😏
🎯 Target: Cashing Out Like a Boss 💸
💰 Profit Target: Aim for $420.00, where the Simple Moving Average (SMA) acts as a strong resistance.
⚠️ Why This Level?: The SMA has historically capped rallies, and we’re seeing signs of overbought conditions with a potential trap for late buyers. Escape with your profits before the trap springs! 🏃♂️
📝 Note: As always, Thief OGs, this is my suggested target. You decide when to pocket the gains — it’s your heist, your rules! 😎
👀 Related Pairs to Watch 🔎
To keep your eyes on the market’s pulse, here are correlated assets to monitor alongside NYSE:UNH :
📈 NYSE:CI (Cigna Corporation): Another healthcare giant, often moves in tandem with NYSE:UNH due to sector trends. Watch for similar bullish setups or divergences. 🩺
📊 NYSE:HUM (Humana Inc.): A key player in the health insurance space, showing high correlation with $UNH. If NYSE:HUM breaks out, it could confirm NYSE:UNH ’s move. 🚀
📡 AMEX:XLV (Health Care Select Sector SPDR Fund): This ETF tracks the broader healthcare sector. A bullish AMEX:XLV strengthens the case for NYSE:UNH ’s rally. 🌟
Key Correlation Point: NYSE:UNH , NYSE:CI , and NYSE:HUM often react to healthcare policy news, earnings cycles, and sector sentiment. Keep an eye on AMEX:XLV for broader sector confirmation. If AMEX:XLV is pumping, NYSE:UNH is likely to follow! 📊💥
📝 Final Notes for the Heist
This setup is designed for Thief OG traders who love a calculated, stylish swing trade. The layering strategy gives you flexibility, the bullish signals provide confidence, and the target keeps it profitable. But always remember: trade at your own risk, and don’t get caught in the market’s traps! 😜
✨ “If you find value in my analysis, a 👍 and 🚀 boost is much appreciated — it helps me share more setups with the community!”
Disclaimer: This is a Thief Style trading strategy, crafted for fun and educational purposes. Always do your own research and manage your risk. Trading involves risks, and I’m not responsible for any losses. Stay sharp, Thief OGs! 🕵️♂️
#UNH #SwingTrade #LayeredEntry #ThiefStrategy #StockMarket #HealthcareStocks #TradingIdeas #BullTrend #TechnicalAnalysis #GoldenCross #MarketWealthMap #TradingView Long 
Long 
Long 
Long
Short 
Long 
Long
UnitedHealth: Deeply oversold but worth a closer lookUnitedHealth (UNH) is the largest private healthcare company in America. Eight million Medicare Advantage members. Optum’s network reaches tens of millions more. It has the data, the reach, and the pricing power. At today’s valuation, it’s worth adding to your watchlist. Forward P/E at 11× versus a five-year average of 14×. Price-to-sales at 0.6×. RSI at levels not seen in decades. Oversold. Under-owned.
Mispriced? Potentially. We must make it very clear that there could be more downside. But upside is also worth considering.
The AI angle is real. UNH’s health data trove is unmatched. AI can strip billions in waste, automating claims, flagging fraud, predicting costly illnesses before they happen. This isn’t science fiction. It’s execution. Done right, it builds margins and widens the moat. Few can play at this scale. UNH can.
Healthcare as a sector trades 20-30% cheaper than the S&P 500. Aging demographics and chronic care demand are long-term tailwinds. A re-rating here could be swift and brutal for anyone short.
Now, the problems. Medical costs are spiking. Medicare Advantage margins are squeezed. Guidance was pulled, and that spooked the market. Leadership turnover added uncertainty.
These are real headwinds. But they’re fixable.
Premium hikes are already being set for 2026. Stephen Hemsley, the architect of UNH’s prior growth, is back. He’s cutting, reviewing, and bringing in outside talent.
Price implications? The market is pricing in permanent damage. That’s why you can buy a market leader at a crisis multiple. If margins recover and AI efficiencies kick in, this stock doesn’t just bounce, it re-rates. The gap from 11× to 14× earnings on UNH’s scale is tens of billions in market cap.
The bear pit is noisy. The bull case is quiet. But it’s there, and it’s strong. Stop losses are important to manage more downside risk.
The forecasts provided herein are intended for informational purposes only and should not be construed as guarantees of future performance. This is an example only to enhance a consumer's understanding of the strategy being described above and is not to be taken as Blueberry Markets providing personal advice. Long 
UnitedHealth (UNH) Shares Plunge Following Earnings ReportUnitedHealth (UNH) Shares Plunge Following Earnings Report
Yesterday, prior to the opening of the main trading session, UnitedHealth released its quarterly results along with forward guidance. As a result, UNH shares dropped by over 7%, signalling deep disappointment among market participants. According to media reports:
→ Earnings per share came in at $4.08, missing analysts’ expectations of $4.48.
→ Revenue guidance was set at $445.5–448 billion, falling short of the anticipated $449.07 billion.
→ Concerns were further fuelled by rising costs and declining profitability, which the company attributed to the continued impact of Medicare funding cuts.
Consequently, the UNH share price dropped to its lowest level of 2025, last seen on 15 May.
Technical Analysis of UNH Stock Chart
In our end-of-May analysis, we updated the descending channel on the UNH stock chart and highlighted that following the recovery from the May low (marked by arrow 1), sellers could regain control. Since then:
→ Throughout June, the share price exhibited signs of supply-demand equilibrium around the psychological $300 level.
→ However, after an unsuccessful rally that formed peak A (which now resembles a bull trap), the balance shifted in favour of the bears. The price began to slide lower along the median line of the descending channel (illustrated by arrow 2).
This pattern was a red flag, particularly against the backdrop of a broadly rising equity market since the beginning of summer. Even if the bulls had hope, yesterday's candle could have completely extinguished it:
→ The session opened with a wide bearish gap.
→ During the day, bulls attempted a recovery, but failed — the candlestick closed at the daily low, leaving a long upper wick, a classic sign of selling pressure.
In this context, we could assume that:
→ Bears may seek to extend their advantage and test the year’s low;
→ The bearish gap area (highlighted in purple), reinforced by the descending channel’s median line, could act as resistance during any potential recovery.
At the same time, the $250 psychological level appears to be a strong support zone. This is backed by the 15 May bullish pin bar formed on record trading volumes — a potential sign of institutional interest in accumulating shares of this healthcare giant in anticipation of a long-term recovery.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice. My UNH Thesis: Betting on a Healthcare Giant's Come BackThe healthcare sector has been in decline, which creates interesting opportunities. I recently talked about a few pharma plays - Eli Lilly, Novo Nordisk, and Pfizer.
Here's why I'm investing in NYSE:UNH :
UnitedHealth Group (UNH) has tanked ~50% in the past year, but the July 29 (VERY SOON) earnings could flip the script. As a historically dominant player, UNH is now undervalued amid sector weakness, offering massive upside if regulatory fears ease.
Here's my full bull case. 👇 FUNDAMENTAL ANALYSIS
Why the Sell-Off? A Perfect Storm of Bad News
UNH crushed the market for 15 straight years (2009-2023) with positive returns, predictable EPS growth, and 134% gains over the last decade.
But 2024 brought chaos:
Feb: Massive cyber attack caused a one-time EPS hit (non-recurring).
Ongoing: DOJ antitrust probe, criminal fraud investigation, rising Medicare costs, and Optum losses.
April: Disastrous Q1 earnings miss + lowered guidance.
Leadership drama: CEO death.
This erased gains (down 7% over 5 years), amplified by healthcare sector outflows—the biggest since 2020. But is this overblown? Signs point to yes. The markets almost always overreact to bad news.
Bullish Signals: Insiders Betting Big
The tide is turning:
Insider Buying Boom: $32M+ in 2024 (vs. $6.6M in 2019), including new CEO/CFO—highest in 15 years.
Congress Buying: Q2 2024 saw net purchases for the first time in 5 years (vs. historical selling).
DOJ Shift: Probe refocusing on pharmacy benefits (PBM) unit, dropping acquisition/monopoly scrutiny—implies no major findings. Great news!
Sector Tailwinds: Healthcare is one of 3 S&P sectors below historical valuations. Super investors (usually tech-obsessed) are piling in, despite the sector's -10% YTD vs. S&P's +13%.
Plus, UNH's dividend yield is at a record ~3% (vs. 1.5% avg), with 16%+ historical growth and 100%+ free cash flow conversion. Rare combo of yield + growth!
Valuation: Screaming Buy?
UNH trades at PE ~11.9 (vs. 10-year avg 23)—a steal.
Analysts project 16.7% EPS CAGR through 2029.
Conservative Scenario: 16.5% EPS growth + PE to 16.5 = $780/share by 2030 (173% total return, 18% CAGR ex-dividends).
Optimistic: PE back to 23 = $1,084/share (280% return).
Models confirm:
DCF (8% FCF growth): ~$484/share (70% upside).
DDM (7% div growth): ~$607/share (112% upside).
Blended Fair Value: ~$545/share (75-90% upside from ~$300). Buy below $436 for 20% safety margin.
Still, there is fear of DOJ uncertainty—investors hate unpredictability and that's why the stock is so low.
Key Catalyst: July 29 Earnings
This could be UNH's "most important report ever." Watch for:
Regulatory/legal updates (DOJ progress).
Full-year guidance revisions.
Metrics like medical loss ratio and PBM performance.
Positive news = potential rocket 🚀. Expectations are low (20 bearish EPS revisions vs. 0 bullish), so a beat could spark volatility... upward.
Risks: Not Without Bumps
Regulatory escalation (e.g., PBM issues) could tank it further.
Short-term headwinds: Medicare costs, sector selling.
Mitigants: DOJ de-risking, strong FCF buffer, insider confidence. Enter cautiously—size positions small.
TECHNICAL ANALYSIS
I also did a little technical analysis:
UNH price is at a resistance level
My EVaR indicator tells me we are in a low-risk area
RSI says the stock is oversold
I added the different price targets for better visualization
THE PLAN
My plan:
Later today, I will allocate 1% to 1.5% of my portfolio to the stock. If it drops, I will continue to DCA. The stock is already really beaten down, and I think a company this large cannot drop much more.
Quick note: I'm just sharing my journey - not financial advice! 😊 Long 
UnitedHealth (UNH) Share Price ReboundsUnitedHealth (UNH) Share Price Rebounds
A month ago, in our analysis of the UNH chart, we:
→ highlighted that UnitedHealth shares had lost nearly 23% in value;
→ drew a descending channel and suggested that bearish pressure could continue, threatening the support level around $450, which had held since early 2022.
Since then, UNH’s stock price decisively broke below that level (as marked by the arrow), falling to around $250 — its lowest point since spring 2020 — before staging a sharp rebound. This steep price movement was driven by a series of fundamental developments, including:
→ the resignation of the CEO and news of a Department of Justice investigation into potential Medicare fraud;
→ UnitedHealth withdrawing its earnings guidance for the coming year;
→ political debates over the Medicaid programme as part of the 2025 budget negotiations;
→ President Trump’s directive to cut prescription drug prices.
Recent news that the new CEO and several top executives have bought tens of millions of dollars’ worth of UNH shares appears to have renewed investor confidence — the share price rose above the $300 mark yesterday.
Technical Analysis of UNH Share Chart
These latest developments justify an update to the descending channel configuration. Of particular note is the gradual decline with limited volatility — a sign that the price is moving along the channel's median line (highlighted on the chart).
In this setup:
→ the bounce from the $250 level points to the lower boundary of the channel;
→ traders may consider a scenario where the current recovery pushes UnitedHealth stock towards the median, after which supply pressure may return and offset the recent dominance of demand.
It’s also possible that the key psychological level of $300 could now act as support.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice. UnitedHealth Group | UNH | Long at $323.00UnitedHealth Group NYSE:UNH currently has a P/E near 15x, steady rising revenue (2024 = $400+ billion), EPS of 6.24x, dividend of 2.2%, and earnings are forecast to grow by 10.8% per year. The stock, however, has plummeted recently due to negative news, rising healthcare costs, CEO changes, and suspension of 2025 outlook. Every company has bumps, but I view solid companies like NYSE:UNH as pure opportunities for long-term investment - especially with America's aging population.
From a technical analysis perspective, the stock price has entered my "crash" simple moving average zone (which currently extends down near $307.00). Personally, this is the zone I am starting a position due to the odds of a future bounce from here. However, I am very aware that there is an open price gap near $265.00 that may get filled this year or early next. I could see a bounce in my crash zone to bring in the bulls and then a drop to that level to heighten the fear. That is another area I plan to grab more shares and build a strong position. But, in case it doesn't extend that low, I have started a position at $223.00, with future investments near $307.00 and below. I doubt this will be a quick turnaround stock - patience is where money is made.
Targets (into 2028):
$375.00
$475.00
$580.00
Long 
UnitedHealth (UNH) Share Price PlummetsUnitedHealth (UNH) Share Price Plummets
UnitedHealth shares crashed by nearly 23% yesterday after the healthcare giant reported weaker-than-expected Q1 2025 results:
→ Earnings per share: actual = $7.20, expected = $7.29
→ Revenue: actual = $109.5bn, expected = $111.5bn
Technical Analysis of UNH Share Chart
As far back as a year ago, we highlighted key support around the $450 level. Yesterday’s negative news caused this support to once again demonstrate its strength by holding back further decline — but will it hold?
Taking the price action marked on the chart as a base, we can establish the structure of a descending channel (shown in red), with the price gapping sharply lower into the bottom half of this channel — and yesterday’s candle high (marked with an arrow) suggests that the median line has turned into resistance.
Yesterday’s candle closed near its lows, so it is reasonable to assume that bearish pressure may persist (with the aim of testing the lower boundary) — in which case, the $450 support zone, in place since early 2022, could be at risk.
This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice. Buy Recommendation Note for UnitedHealth Group (UNH)Recommendation: Buy
Buy Zone: $551.50 - $557.00
Target: $600.00 (Short-Term), $650.00 (Medium-Term)
Rationale
Strong Fundamentals: UnitedHealth Group has consistently delivered robust revenue growth driven by its diversified healthcare services and insurance offerings.
Industry Leadership: As a leader in the healthcare sector, UNH benefits from its scale, market share, and innovative healthcare solutions, ensuring long-term stability.
Positive Outlook: Recent developments and earnings reports indicate strong growth potential, supported by increasing demand for managed healthcare services.
Valuation: Current levels provide a favorable risk-to-reward ratio for entry, with the stock trading near a key support zone.
Technical Analysis
The stock has shown strong support in the $551.50 - $557 range, making it an attractive buying opportunity. A breakout above $560 could signal a bullish continuation toward the target zones.
Technical Analysis
The stock has shown strong support in the $551.50 - $557 range, making it an attractive buying opportunity. A breakout above $560 could signal a bullish continuation toward the target zones.
Disclaimer:
This note is for study and informational purposes only. The recommendations and price levels mentioned are based on market observations and are not a guarantee of performance. Please consult with a licensed financial advisor and carefully consider your risk tolerance before making any investment decisions. Past performance is not indicative of future results. Investing in stocks carries inherent risks, including the potential loss of capital. Long 
Long 
